Orthomimetics reaches patient recruitment milestone in key European clinical study.

Orthomimetics, the UK based regenerative medicine company has reported treatment of the tenth patient in a clinical study for Chondromimetic, a dual-layered implant for the repair of damaged cartilage and bone.

The single-centre study is being conducted under the supervision of world-renowned surgeon Professor Laszlo Hangody and is evaluating the safety and efficacy of Chondromimetic using multiple outcome variables.

Ten patients are enrolled in phase one of the clinical study and early MRI results look promising. The second phase of the study will evaluate the new Chondromimetic Instrumentation System for arthroscopic delivery of the implant. It is envisaged this new minimally invasive approach will make the surgical procedure quicker and easier and potentially reduce the time that patients must remain in hospital.

Building on this clinical data, Orthomimetics is hoping to expand its clinical research programme to a further 10 sites in Europe with the aim of recruiting a total of 200 patients who will be collected in a Clinical Register to further validate the technique and patient benefits.

Commenting on the trial, Andrew Lynn, CEO of Orthomimetics said:

“We are extremely pleased to report the trial has been conducted to the schedule we set out and that these early outcomes are encouraging. We look forward to building on this progress to establish a set of high-quality clinical data to support the long-term efficacy of Chondromimetic and our commercial efforts.”

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button